Recurrent Osteosarcoma Completed Phase 2 Trials for Irinotecan (DB00762)

Also known as: Osteosarcoma recurrent / Osteogenic sarcoma recurrent

IndicationStatusPhase
DBCOND0028757 (Recurrent Osteosarcoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00004078Irinotecan in Treating Children With Refractory Solid TumorsTreatment